Abstract
During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Current Pharmaceutical Design
Title: Cell Death in Mammalian Development
Volume: 14 Issue: 2
Author(s): Z. Zakeri, C. Penaloza, S. Orlanski, Y. Ye, T. Entezari-Zaher and M. Javdan
Affiliation:
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Abstract: During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Export Options
About this article
Cite this article as:
Zakeri Z., Penaloza C., Orlanski S., Ye Y., Entezari-Zaher T. and Javdan M., Cell Death in Mammalian Development, Current Pharmaceutical Design 2008; 14 (2) . https://dx.doi.org/10.2174/138161208783378789
DOI https://dx.doi.org/10.2174/138161208783378789 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction
CNS & Neurological Disorders - Drug Targets Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Kaempferol-3-<i>O</i>-Rhamnoside Inhibits the Proliferation of Jurkat Cells Through Jun Amino-Terminal Kinase Signaling
The Natural Products Journal Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design Inhibition of Protein Misfolding and Aggregation by Small Rationally-Designed Peptides
Current Pharmaceutical Design